NMN Study #3
Harvard Medical School and Metro International Biotech made a joint study on how MIB-626, a pharmaceutical-grade preparation of NMN is able to increase blood levels of NAD+ in middle-aged, older adults in two weeks.
There has been plenty of studies with encouraging results on NAD+ boosts in human cells and mice, but there are very few studies that examine the efficacy of these compounds in the human body. It might be due to the fact that there isn’t a consensus on what the safe doses of NMN are.
The participants took 2 doses of 500mg of MIB-626 daily, for two weeks. The results showed that it was safe and that, after two weeks, there was a significant rise in NAD+ blood levels. In fact, it was doubled. One of the goals of this study is to design efficacy trials for NMN in diseases.
This study was founded by Harvard researcher Dr. David Sinclair, who’s been studying and testing NMN and NAD+ for years. He’s even tested NAD+ boosting pills with US Special Forces.
The results showed that 1,000mg daily was well tolerated by the human body. There were no serious adverse reactions. Only one of the participants had some alterations in blood levels of liver enzymes. There were no changes in the body mass index of the participants. It was tested in middle-aged and older adults who were overweight and obese but medically stable.
MIB-626 results gave evidence that it was able to triple NAD+ blood levels. This comes to show how NMN is metabolized after administration. It should be noted that this study was not made to evaluate efficacy but tolerance, but the results show that for incoming efficacy trials, 1,000mg (or even more) of NMN should be used. Doses of less than 1,000mg didn’t show any consistent raise in NAD+ blood levels.
Also, the results of this study agree with the resulting data of previously performed trials: it seems as though NR and NMN have no significant effects on fat, glucose, insulin, and uric acid levels. However, this study was also not long enough to study or detect changes in insulin sensitivity and glucose metabolism.
Some researchers say that NMN doesn’t get into cells, and some others have proven that there are “transporters” that carry NMN into cells. Dr. Sinclair says that all those findings are still open to debate and that, the truth might be that nobody really knows how NMN works, but that it does work.
This study will bring into light how other pharmaceutical-grade NMN products could boost NAD+ blood levels. If other NMN formulations are able to replicate MIB-626, we might see clinical trials of NAD+ boosters taking form.
https://www.nmn.com/news/nmn-tablet-blood-nad-levels-humans